Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 8:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 294 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Extensive-stage Small Cell Lung Carcinoma Clear all
Terminated Phase 2 Interventional

Oxaliplatin/CPT-11 for Extensive Stage Small Cell Lung Cancer

NCT00316433
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Irinotecan (CPT-11), Oxaliplatin (Eloxatin)
Drug
Lead sponsor
Swedish Medical Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 4, 2007 · Synced Sep 28, 2026, 8:31 PM EDT
Withdrawn Phase 2 Interventional

INNO-206 in Patients With Small Cell Lung Cancer (SCLC)

NCT00472771
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
INNO-206
Drug
Lead sponsor
CytRx
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
7
States / cities
Chicago, Illinois • Billings, Montana • Albany, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2012 · Synced Sep 28, 2026, 8:31 PM EDT
Completed Phase 2 Interventional Results available

Irinotecan and Carboplatin in Treating Patients With Metastatic or Recurrent Small Cell Lung Cancer

NCT00387660
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, irinotecan
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 9, 2018 · Synced Sep 28, 2026, 8:31 PM EDT
Recruiting Phase 2 Interventional

Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer

NCT07057791
View directory record Official record
Conditions
Extensive Stage Lung Small Cell Cancer
Interventions
Ivonescimab 10 mg/kg, Ivonescimab 20 mg/kg
Drug
Lead sponsor
PrECOG, LLC.
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
13
States / cities
Miami, Florida • Chicago, Illinois • Baltimore, Maryland + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 28, 2026, 8:31 PM EDT
Recruiting Phase 1 Interventional

Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung Cancer

NCT05244239
View directory record Official record
Conditions
Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Lurbinectedin, Palliative Radiation Therapy
Drug · Radiation
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Sep 28, 2026, 8:31 PM EDT
Terminated Phase 2 Interventional Results available

Study of Pemetrexed and Gemcitabine for Patients With a New Diagnosis of Extensive-Stage Small Cell Lung Cancer

NCT00129974
View directory record Official record
Conditions
Carcinoma, Small Cell
Interventions
pemetrexed and gemcitabine
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
3
States / cities
Boston, Massachusetts • Quincy, Massachusetts • Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 15, 2017 · Synced Sep 28, 2026, 8:31 PM EDT
Completed Phase 2 Interventional Results available

Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer

NCT00695292
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
irinotecan, Carboplatin, sunitinib
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
10
States / cities
Fort Myers, Florida • Orlando, Florida • Gainesville, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2021 · Synced Sep 28, 2026, 8:31 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer

NCT01737502
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Carcinoma, Lung Adenocarcinoma, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Small Cell Lung Carcinoma, Squamous Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Interventions
Auranofin, Sirolimus, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
2
States / cities
Scottsdale, Arizona • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Sep 28, 2026, 8:31 PM EDT
Completed Phase 2 Interventional

Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors

NCT00003269
View directory record Official record
Conditions
Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Lymphoma, Ovarian Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
sargramostim, amifostine trihydrate, cisplatin, cyclophosphamide, etoposide
Biological · Drug
Lead sponsor
Scripps Health
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jan 9, 2011 · Synced Sep 28, 2026, 8:31 PM EDT
Completed Phase 2 Interventional

Pemetrexed Disodium and Carboplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer

NCT00227565
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, pemetrexed disodium, radiation
Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
148
States / cities
Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 97 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2016 · Synced Sep 28, 2026, 8:31 PM EDT
Completed No phase listed Observational

Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer

NCT00897793
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Prostate Cancer
Interventions
venipuncture, radiation therapy
Procedure · Radiation
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 11, 2013 · Synced Sep 28, 2026, 8:31 PM EDT
Recruiting Phase 3 Interventional

BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)

NCT07625644
View directory record Official record
Conditions
Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma, Sclc, SCLC,Extensive Stage, Lung Cancer, Lung Cancer Metastatic, Lung Cancer Stage IV
Interventions
BL-M14D1 and Atezolizumab, Carboplatin+ Etoposide + Atezolizumab followed by Atezolizumab and Lurbinectedin
Drug
Lead sponsor
SystImmune Inc.
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
7
States / cities
Springdale, Arkansas • Glendale, California • Long Beach, California + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Sep 28, 2026, 8:31 PM EDT
Terminated Phase 1 Interventional

A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer

NCT02819999
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Rovalpituzumab Tesirine, Cisplatin, Etoposide
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
11
States / cities
Aurora, Colorado • Denver, Colorado • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Sep 28, 2026, 8:31 PM EDT
Completed Phase 2 Interventional Results available

Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer

NCT03382561
View directory record Official record
Conditions
Extensive Stage Lung Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma
Interventions
Carboplatin, Cisplatin, Etoposide, Nivolumab
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
779
States / cities
Anchorage, Alaska • Hot Springs, Arkansas • Anaheim, California + 518 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Sep 28, 2026, 8:31 PM EDT
Completed No phase listed Observational

Psychosocial Adjustment After Radiation Therapy in Patients With Cancer

NCT00905086
View directory record Official record
Conditions
Breast Cancer, Cognitive/Functional Effects, Colorectal Cancer, Lung Cancer, Prostate Cancer, Psychosocial Effects of Cancer and Its Treatment
Interventions
questionnaire administration, cognitive assessment, psychosocial assessment and care, quality-of-life assessment
Other · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 29, 2015 · Synced Sep 28, 2026, 8:31 PM EDT
Not listed Phase 3 Interventional

Study of Palifosfamide-tris in Combination With Carboplatin and Etoposide in Chemotherapy Naïve Patients With Extensive-Stage Small Cell Lung Cancer (The MATISSE Study)

NCT01555710
View directory record Official record
Conditions
Extensive-Stage Small Cell Lung Cancer
Interventions
Carboplatin, Palifosfamide-tris, Etoposide
Drug
Lead sponsor
Alaunos Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
548 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
40
States / cities
Birmingham, Alabama • Los Angeles, California • Santa Rosa, California + 36 more
Source: ClinicalTrials.gov public record
Updated May 20, 2013 · Synced Sep 28, 2026, 8:31 PM EDT
Withdrawn Phase 2 Interventional

ALCMI-005: Pembrolizumab and Epacadostat in Treating Patients With Extensive Stage Small Cell Lung Cancer

NCT03402880
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Carcinoma
Interventions
Pembrolizumab, Epacadostat, Laboratory Biomarker Analysis
Biological · Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Duarte, California • South Pasadena, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 28, 2026, 8:31 PM EDT
Active, not recruiting Phase 2 Interventional

Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer

NCT04397003
View directory record Official record
Conditions
Extensive-stage Small Cell Lung Cancer
Interventions
Neoantigen DNA vaccine, Durvalumab, TDS-IM v2.0 Device, Peripheral blood draws
Biological · Drug · Device + 1 more
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Sep 28, 2026, 8:31 PM EDT
Completed Phase 2 Interventional

Cisplatin, Irinotecan, and Bevacizumab, in Treating Patients With Small Cell Lung Cancer

NCT00118235
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Cancer
Interventions
cisplatin, irinotecan hydrochloride, bevacizumab, laboratory biomarker analysis
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
2
States / cities
Chicago, Illinois • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 16, 2014 · Synced Sep 28, 2026, 8:31 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer

NCT07155174
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
ABBV-706, Atezolizumab, Etoposide, Carboplatin, Lurbinectedin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
11
States / cities
New Haven, Connecticut • Gainesville, Florida • Ocala, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Sep 28, 2026, 8:31 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Whole-Brain Radiation Therapy With or Without Hippocampal Avoidance in Limited Stage or Extensive Stage Small Cell Lung Cancer

NCT02635009
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Carcinoma, Limited Stage Small Cell Lung Carcinoma
Interventions
Three-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy
Radiation
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
270
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Tucson, Arizona + 217 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 28, 2026, 8:31 PM EDT
Terminated Phase 1 Interventional

A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC

NCT03963414
View directory record Official record
Conditions
Small Cell Lung Carcinoma
Interventions
Durvalumab + Tremelimumab in combination with carboplatin and etoposide, Durvalumab in combination with carboplatin and etoposide
Combination Product
Lead sponsor
University of Nebraska
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 27, 2023 · Synced Sep 28, 2026, 8:31 PM EDT
Completed Phase 1 Interventional

Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer

NCT00006368
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Breast Cancer, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Lung Cancer, Lymphoma, Melanoma (Skin), Neoplastic Syndrome
Interventions
yttrium Y 90-edotreotide
Radiation
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 30, 2013 · Synced Sep 28, 2026, 8:31 PM EDT
Completed Not applicable Interventional

T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors

NCT00433407
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer, Sarcoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
trastuzumab
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 3, 2012 · Synced Sep 28, 2026, 8:31 PM EDT